Doctor of Osteopathy Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Patrick Karl

Interventional Pain Medicine Jesup, GA Doctor of Osteopathy

NPI 1073795142 CMS profile 276312

1907 Sunset Blvd, Jesup, GA 31545

Open in the dashboard

General payments

$2,413

166 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Patrick Karl of Jesup, GA is reported in the CMS Open Payments database as having received $2,413 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $267 17
2021 General $784 59
2020 General $661 50
2019 General $702 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Karl
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Patrick Karl were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Patrick Karl Interventional Pain Medicine median Middle half National median
2019 $702 $684 $216–$2,079 $163
2020 $661 $382 $122–$1,109 $114
2021 $784 $552 $167–$1,554 $132
2022 $267 $605 $187–$1,924 $149
2023 $0 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Biodelivery Sciences International, Inc. $498 47 payments
  2. Boston Scientific Corporation $362 25 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $329 26 payments
  4. Nevro Corp. $310 11 payments
  5. Collegium Pharmaceutical, Inc. $219 16 payments
  6. Forte Bio-Pharma LLC $100 2 payments
  7. Supernus Pharmaceuticals, Inc. $88 6 payments
  8. RedHill Biopharma Inc. $82 5 payments
  9. Biohaven Pharmaceuticals, Inc. $75 4 payments
  10. Pfizer Inc. $72 5 payments
  11. Other $278 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,392 165 payments
  2. Education $21 1 payment
Products named General payments · program years 2019–2022
  1. RELISTOR $260 20 payments
  2. Senza Spinal Cord Stimulation System $252 7 payments
  3. BELBUCA $231 26 payments
  4. BUNAVAIL 4.2 mg single pouch $229 18 payments
  5. BUNAVAIL 6.3 mg 30-count box $229 18 payments
  6. BUNAVAIL 2.1 mg single pouch $229 18 payments
  7. BUNAVAIL 4.2 mg 30-count box $229 18 payments
  8. BUNAVAIL 2.1 mg 30-count box $229 18 payments
  9. XTAMPZA $170 12 payments
  10. NALOCET $100 2 payments
  11. Other $1,354 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record